The fixed-dose combination of ASC36 and ASC35 (ASC36_35 FDC) showed superior weight reduction compared to eloralintide paired with tirzepatide in a diet-induced obese (DIO) animal model.

/PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") announces that preclinical findings of ASC36_35 FDC, a once-monthly injection co-formulation of ASC36, a peptide amylin receptor agonist, and ASC35, a peptide GLP-1R/GIPR agonist, for obesity treatment, will be shared in a short oral discussion at the 62nd European Association for the Study of Diabetes (EASD) Annual Meeting in Milan, Italy. The results highlight better weight loss than the eloralintide and tirzepatide combination in a diet-induced obese (DIO) animal model.

Details of the Short Oral Discussion

Abstract Title: Co-formulation of ASC36 and ASC35, once-monthly amylin receptor agonist and GLP-1R/GIPR agonist, showed superior weight loss to eloralintide/tirzepatide combo in DIO rats

Short Oral Discussion Event F

Short Oral Discussion Session: SO 066 Emerging agents: amylin, oral molecules and beyond

Short Oral Discussion Station 11

Presentation Time: Thursday, October 1, 2026, 14:00 - 15:00 CEST

Presentation Number: 768

"We believe the co-formulation of ASC36 and ASC35 has the potential to deliver greater weight loss in people with obesity than the eloralintide/tirzepatide combination, based on these preclinical results," said Jinzi Jason Wu, Ph.D., Founder, Chairman and CEO of Ascletis. "The selection of these data for oral discussion at EASD 2026 reflects the value of advancing new treatment options for patients with obesity."

About ASC36_35 FDC

ASC36_35 FDC, a once-monthly subcutaneous (SQ) injection co-formulation of ASC36 and ASC35, is a potentially first-in-class drug candidate targeting three validated targets of amylin receptor, GLP-1R and GIPR. ASC36_35 FDC once-monthly co-formulation is Self-Assembling Lipid Depot (SALD) formulation, developed in-house utilizing Ascletis' Ultra-Long-Acting Platform (ULAP) technology.

About the European Association for the Study of Diabetes (EASD)

Founded in 1965 and based in Düsseldorf, Germany, the European Association for the Study of Diabetes (EASD) aims to encourage and support research in the field of diabetes, the rapid diffusion of acquired knowledge and to facilitate its application. The EASD Annual Meeting features groundbreaking basic research, cutting-edge clinical trial results and in-depth expert debates. The 62nd EASD Annual Meeting will be held in Milan, Italy, from September 28 to October 2, 2026.

About Ascletis Pharma Inc.

Ascletis Pharma Inc. is a fully integrated biotechnology company focused on the development and commercialization of potentially best-in-class and first-in-class therapeutics to treat metabolic diseases. Utilizing its proprietary Artificial Intelligence-assisted Structure-Based Drug Discovery (AISBDD) and Ultra-Long-Acting Platform (ULAP) technologies as well as Peptide Oral Transport ENhancement Technology (POTENT), Ascletis has developed multiple drug candidates in-house, including both small molecules and peptides, such as its lead program, ASC30, a small molecule GLP-1R agonist designed to be administered once daily orally and once monthly to once quarterly subcutaneously as a treatment therapy and a maintenance therapy for chronic weight management; ASC36, an amylin receptor peptide agonist, ASC35, a once-monthly subcutaneously administered GLP-1R/GIPR dual peptide agonist and ASC37, a GLP-1R/GIPR/GCGR triple peptide agonist, ASC39, an eloralintide-like potent and amylin-selective oral small molecule amylin receptor agonist, ASC30_39 FDC, a fixed-dose combination (FDC) of ASC30 (GLP-1 RA) and ASC39 (amylin RA), ASC30_48 FDC, a fixed-dose combination (FDC) of ASC30 (GLP-1 RA) and ASC48 (GIP RA), for chronic weight management. Ascletis is listed on the Hong Kong Stock Exchange (1672.HK).

For more information, please visit www.ascletis.com.

Contact:
Peter Vozzo
ICR Healthcare
443-231-0505 (U.S.)
[email protected]

Ascletis Pharma Inc. PR and IR Teams
+86-181-0650-9129 (China)
[email protected]
[email protected]

SOURCE Ascletis Pharma Inc.